Background
==========

Many researchers have studied the feasibility of gene expression profiling to improve the prognosis of cancer patients and have shown that gene expression signatures can better predict the outcome of cancer patients than conventional clinical criteria in many cancer types \[[@B1]-[@B4]\]. A few of the discovered signatures are now in large clinical trials to confirm their prognostic value \[[@B5],[@B6]\]. However, there are also concerns about the usefulness of the gene expression signatures because several problems remain unresolved \[[@B7]-[@B9]\]. These problems include poor overlap among discovered gene signatures, the unstable nature of gene expression signatures, and poor performance of signatures when applied to other datasets \[[@B7],[@B9]-[@B11]\].

Researchers have applied either top-down or bottom-up approaches to discover prognostic gene signatures \[[@B12]\]. Most researchers have used the top-down approach in which samples are split into training and testing sets and gene signatures are developed by discovering genes that show a high correlation between expression and clinical information \[[@B2],[@B13]-[@B19]\]. In the bottom-up approach, gene signatures developed from other biological models are applied to gene expression datasets to classify patients into clinically distinct groups \[[@B12],[@B20]\]. One advantage of the bottom-up approach is that it affords a straightforward understanding of the underlying biological process behind the discovered gene signature \[[@B12]\]. Similarly, the recently developed gene set enrichment analysis (GSEA) and similar methods are promising tools for high-throughput data analysis. These methods enable researchers to identify significantly changed biological themes and pathways from gene expression data by observing changes in expression using pre-defined gene sets \[[@B21],[@B22]\]. Another method, named globaltest, was recently developed to test the association of a pathway with survival using gene expression data \[[@B23]\].

A gene signature is useless if it works well only on the dataset from which it was developed. Thus, recent work includes external validation of developed signatures as a necessary step that will reinforce the applicability of gene signatures to other datasets \[[@B14],[@B15],[@B24]\]. Here, we suggest a simple but very effective approach to identify gene signatures that are prognostic in multiple datasets. Rather than developing a signature from one dataset and validating it in other datasets, we suggest simultaneously testing multiple pre-defined gene signatures on multiple datasets to identify signatures that are prognostic in as many independent datasets as possible. By exhaustively testing all combinations of gene sets and datasets, our approach guarantees that the best gene signature will be identified among a pool of pre-defined gene sets. Moreover, our approach will enable better understanding of the underlying biology of disease by observing the patterns of association between gene expression and clinical parameters at multiple gene set levels.

In this work, we applied a bottom-up, gene sets approach to multiple datasets to determine gene signatures for prognosis of breast cancer patients. We chose breast cancer because there are several high-quality breast cancer gene expression datasets with survival or recurrence information. Our goal was to identify prognostic gene signatures useful in as many independent datasets as possible. For this, we collected 12 different datasets comprising 1,756 tumor samples and prepared 2,411 gene sets from diverse sources including gene ontology, biological pathways, and previously identified prognostic gene signatures for breast cancer. For each gene set, we performed survival analysis to test if the gene set could classify patients into clinically distinct groups. We also evaluated each gene set for the accuracy of outcome prediction.

Results
=======

Selection of gene sets for prognosis of survival or recurrence
--------------------------------------------------------------

Analysis of 12 datasets (Table [1](#T1){ref-type="table"}) with 2,411 gene sets (Table [2](#T2){ref-type="table"}) including 32 gene sets previously identified as prognostic in breast and other cancers (Table [3](#T3){ref-type="table"}) revealed that many of the gene sets related to cell cycle or proliferation were best discriminating between good and poor prognosis groups. Table [4](#T4){ref-type="table"} presents the 20 most highly prognostic gene sets identified by two-means clustering of samples. Most of these top gene sets were related to cell cycle, mitosis, proliferation, and DNA replication as well as gene sets previously identified as prognostic in breast cancer such as 11823860_ST2, 17076897_ADF3, and 16478745_ST1 (Table [4](#T4){ref-type="table"}). Kaplan-Meier plots of 12 datasets showed that the 11823860_ST2 gene set classified patients into two groups (poor or good prognosis) according to differences in survival or recurrence in eight of 12 datasets (Figure [1](#F1){ref-type="fig"}). Because breast cancers are heterogeneous and may comprise three to six subtypes \[[@B25]-[@B27]\], we also applied k-means clustering with k = 3, 4, 5, and 6 to each dataset to divide samples into three, four, five, and six subtypes respectively and performed log-rank test to infer the significance of differences in survival between the groups. Again, we found that gene sets related to cell cycle or proliferation were best discriminating between groups with different clinical outcomes (Additional data file [1](#S1){ref-type="supplementary-material"}, Supplementary Table 1, 2, 3, and 4). The 11823860_ST2 gene set, which was ranked as the first in two-means clustering analysis (Table [4](#T4){ref-type="table"}), was ranked as the first in four (Supplementary Table 2) and the fifth in three (Supplementary Table 1) and the tenth in five and six-means clustering (Supplementary Table 3 and 4).

###### 

Breast cancer datasets analyzed in this study

  Study           Platform         Samples   Data source
  --------------- ---------------- --------- -----------------------------------------------------
  Bild            Affymetrix       169       \*GSE3143
  Miller          Affymetrix       251       GSE3494
  Oh              Oligos Agilent   67        <https://genome.unc.edu/pubsup/breastGEO/>
  Pawitan         Affymetrix       159       GSE1456
  Sorlie_1        Spotted cDNA     76        GSE3193
  Sorlie_2        Spotted cDNA     39        <http://genome-www5.stanford.edu/>
  Sotiriou_1      Spotted cDNA     99        <http://www.pnas.org/cgi/content/full/100/18/10393>
  Sotiriou_2      Affymetrix       187       GSE2990
  Van de Vijver   oligos Agilent   295       <http://www.rii.com/publications/2002/nejm.html>
  Wang            Affymetrix       286       GSE2034
  Weigelt         Oligos Agilent   79        <https://genome.unc.edu/pubsup/breastGEO/>
  West            Affymetrix       49        <http://data.cgt.duke.edu/west.php>
                                             
  Total                            1756      

\*GSE: gene expression series number in GEO (gene expression omnibus)

###### 

Number of gene sets in each category

  Category                             Number
  ------------------------------------ --------
  GO Biological Process (BP)           735
  GO Molecular Functions (MF)          648
  Biological Pathways                  198
  InterPro Domains                     798
  Breast and other Cancer Signatures   32
                                       
  Total                                2411

###### 

Thirty-two prognostic gene sets prepared from published reports

  Gene set           Number (reported)   Number (unique)   Reference
  ------------------ ------------------- ----------------- ----------------------------
  \*11823860_ST2     231                 164               van\'t Veer et al. \[13\]
  11823860_ST3       2,460               1,818             van\'t Veer et al. \[13\]
  11823860_ST4       430                 314               van\'t Veer et al. \[13\]
  12490681_70        70                  50                van de Vijver \[1\]
  12747878_ST2       177                 144               Huang et al. \[52\]
  12747878_ST3       168                 160               Huang et al. \[52\]
  12917485_ST6       606                 564               Sotiriou et al. \[18\]
  12917485_ST7       137                 126               Sotiriou et al. \[18\]
  12917485_ST8       706                 635               Sotiriou et al. \[18\]
  12917485_ST9       485                 402               Sotiriou et al. \[18\]
  14737219_CSR       512                 459               Chang et al. \[3\]
  14737219_USR       677                 611               Chang et al. \[3\]
  15034139_T2        45                  31                Zhao et al. \[53\]
  15073102_4         4                   4                 Glinsky et al. \[54\]
  15073102_6         6                   6                 Glinsky et al. \[54\]
  15073102_13        12                  12                Glinsky et al. \[54\]
  15073102_14        14                  14                Glinsky et al. \[54\]
  15591335_F1        21                  21                Paik et al. \[6\]
  15721473_T3        76                  68                Wang et al. \[2\]
  15931389_T3_stem   11                  11                Glinsky et al. \[55\]
  15931389_ST2_14    14                  14                Glinsky et al. \[55\]
  15931389_ST2_CNS   11                  11                Glinsky et al. \[55\]
  16141321_SDC2      500                 398               Miller et al. \[19\]
  16273092_catenin   98                  76                Bild et al. \[20\]
  16273092_E2F3      298                 238               Bild et al. \[20\]
  16273092_myc       332                 192               Bild et al. \[20\]
  16273092_RAS       348                 248               Bild et al. \[20\]
  16273092_SRC       75                  58                Bild et al. \[20\]
  16280042_AF1       64                  61                Pawitan et al. \[16\]
  16478745_ST1       242                 207               Sotiriou et al. \[15\]
  16707453_ST3       101                 86                Schuetz et al. \[56\]
  17076897_ADF3      52                  52                Teschendorff et al. \[24\]

\*Eight-digit number represents PubMed id of a reference

###### 

Top 20 prognostic gene sets identified by two-means clustering in breast cancer gene expression datasets

  Gene set                                \*category   Bild   Miller   Oh      Pawitan   Sorlie_1   Sorlie_2   Sotiriou_1   Sotiriou_2   van de Vijver   Wang    Weigelt   West   ^\#^freq   ^%^mean
  --------------------------------------- ------------ ------ -------- ------- --------- ---------- ---------- ------------ ------------ --------------- ------- --------- ------ ---------- ---------
  11823860_ST2                            BR           1.32   7.21     10.02   22.68     8.87       0.44       4.51         8.18         45.51           8.19    0         0.97   8          9.83
  mitotic checkpoint                      BP           7.51   13.34    2.91    13.57     0.07       0.03       4.08         9.59         30.78           12.49   0.01      3.57   7          8.16
  Cell_cycle_KEGG_GenMAPP                 PW           7.2    12.05    2.08    11.46     4.28       0.31       2.75         9.33         40.26           6.93    0.01      0.03   7          8.06
  cell division                           BP           4.37   10.47    3.46    13.81     6.05       0          2.14         7.69         32.14           15.18   0.02      0.06   7          7.95
  cation efflux protein                   IP           7.94   9.69     2.16    15.77     4.16       2.41       1.96         10.45        24.69           10.04   0.51      0.21   7          7.5
  cyclin, C-terminal                      IP           3.88   15.25    6.72    16.84     5.65       0.07       2.64         3.84         21.12           7.7     0.69      0.23   7          7.05
  DNA repair                              BP           2.04   7.15     4.58    9.13      0.09       0.02       6.61         8.4          35.15           6.97    0.13      1.53   7          6.82
  cyclin, N-terminal domain               IP           3.4    15.66    2.50    10.93     5.5        0.3        4.37         3.91         26.72           7.28    1.03      0.03   7          6.8
  protein tyrosine phosphatase activity   MF           9.45   4.03     8.29    9.19      4.51       0.55       2.55         0.46         24.1            9.25    0         2.84   7          6.27
  protein domain specific binding         MF           6.56   5.32     0       10.73     0.14       1.24       12.14        6.81         15.53           2.69    10.09     0.66   7          5.99
  DNA metabolism                          BP           4.08   8.01     1.81    10.15     0.06       0.17       5.06         4.88         26.2            8.88    0.64      0.3    7          5.85
  identical protein binding               MF           0.18   8.04     8.35    9.55      0.12       5.3        8.79         4.09         19.64           0.01    0.97      0.12   7          5.43
  water transport                         BP           0.01   10.23    5.85    5.26      0.45       5.25       1.57         0.42         3.97            0.91    6.13      5.14   7          3.77
  17076897_ADF3                           BR           3.15   14.49    4.06    19.84     0.1        2.59       2.31         12.03        48.93           18.04   0         2.39   6          10.66
  mitosis                                 BP           6.45   13.81    2.22    16.95     1.35       0.1        2.23         9.05         37.87           11.43   0         0.16   6          8.47
  16478745_ST1                            BR           5.49   10.52    3.2     13.32     1.04       0          2.55         11.64        39.05           12.51   0.29      0.53   6          8.35
  Pyrimidine metabolism_KEGG              PW           4.28   7.84     4.35    25.6      0.61       0.46       2.07         8.04         42.75           3.12    0         0.77   6          8.32
  14737219_USR                            BR           4.27   10.25    3.72    13.61     0.99       0.06       1.96         10.86        39.37           11.4    0.16      0.2    6          8.07
  cytokinesis                             BP           2.6    8.9      3.91    17.06     0.03       0.91       0.22         8.68         48.68           5.24    0.16      0.17   6          8.05
  14737219_CSR                            BR           0.51   10.7     3.13    15.5      7.45       0.08       4.25         1.43         39.65           7.32    0.38      2.3    6          7.73

Values are chi-square values from log-rank test.

\#frequency: The number of cases in which chi-square value is over 3.84

\*category: BP-GO Biological Processes, BR-Breast cancer prognostic signatures, MF-GO Molecular Function, PW-KEGG and GenMAPP pathways, IP-InterPro domains

^%^mean: Mean of 12 chi-square values

![**Kaplan-Meier survival curves for the two prognostic classes of breast cancers.** In each dataset, patients were divided into two groups (poor and good prognostic groups) based on the gene expression pattern in the 11823860_ST2 gene set, and their survival or recurrence proportions were then plotted. The log-rank test was used to infer the statistical significance of survival or recurrence differences between the two groups. In each graph, the x-axis represents overall or relapse-free survival years and the y-axis represents the proportion of overall survival (A, B, C, D, E, F, I, and K) or relapse-free survival (G, H, J, and L). Black indicates poor prognosis and red indicates good prognosis.](1471-2164-9-177-1){#F1}

Unadjusted and adjusted hazard ratios
-------------------------------------

We then calculated unadjusted hazard ratios for three selected gene sets within the 12 datasets (Table [5](#T5){ref-type="table"}). These three gene sets showed significant (P \< 0.05) unadjusted hazard ratios in six or seven of the 12 datasets irrespective of microarray platforms. For example, the Sotiriou_2, Wang, and Pawitan datasets used the Affymetrix U133A platform, the van de Vijver dataset used Agilent oligomers, and the Sorlie_1 dataset used cDNA arrays. This confirms that many gene sets related to cell cycle and proliferation are prognostic irrespective of the microarray platform. We also calculated adjusted hazard ratios for the 11823860_ST2 gene set in the three datasets (Sotiriou_2, van de Vijver, and Sorlie_1) for available clinical parameters such as grade, lymph node status, tumor size, age, and estrogen receptor (ER) status (Additional data file [2](#S2){ref-type="supplementary-material"}, Supplementary Table 5, 6 and 7). The 11823860_ST2 gene set proved significant even after adjustment for other clinical parameters in the three datasets, verifying that the 11823860_ST2 gene set contains additional prognostic value over existing prognostic clinical parameters.

###### 

Hazard ratios and P values for the top three gene signatures in 12 datasets

  Datasets        11823860_ST2                                 Mitotic checkpoint                  Cell_cycle_KEGG
  --------------- -------------------------------------------- ----------------------------------- -----------------------------------
  Bild            **6.35 \***^\#^**(1.23--32.2) p = 0.0256**   2.88 (0.686--12.1) p = 0.148        1.13 (0.407--3.11) p = 0.819
  Miller          1.29 (0.297--5.63) p = 0.731                 0.942 (0.269--3.3) p = 0.925        1.37 (0.547--3.41) p = 0.504
  Oh              4.72 (0.834--26.7) p = 0.0794                3.87 (0.792--18.9) p = 0.0944       2.07 (0.728--5.9) p = 0.172
  Pawitan         **34.6 (4.94--242) p = 3.57e-4**             **11.9 (2.84--49.9) p = 7.1e-4**    **5.21 (1.97--13.8) p = 8.6e-4**
  Sorlie_1        **6.84 (1.75--26.7) p = 0.00568**            **4.73 (1.46--15.3) p = 0.00953**   **2.07 (1.07--4.01) p = 0.0312**
  Sorlie_2        3.28 (0.29--46.9) p = 0.381                  1.99 (0.308--12.8) p = 0.471        1.33 (0.319--5.57) p = 0.695
  Sotiriou_1      27.3 (2.60--287) p = 0.0582                  **64.2 (2.22--1854) p = 0.0153**    **5.58 (1.19--26.20 p = 0.0296**
  Sotiriou_2      **5.22 (1.63--16.8) p = 0.00549**            **3.13 (1.17--8.42) p = 0.0234**    **2.6 (1.24--5.44) p = 0.0113**
  Van de Vijver   **62.3 (17.7--219) p = 1.12e-10**            **8.8 (4.18--18.5) p = 1.05e-8**    **4.03 (2.37--6.85) p = 2.73e-7**
  Wang            **7.48 (2.78--20.1) p = 6.92e-5**            **2.73 (1.22--6.1) p = 0.0144**     **3.78 (1.89--7.55) p = 1.66e-4**
  Wiegelt         2.00 (0.152--26.0) p = 0.597                 1.40 (0.15--13.0) p = 0.769         1.25 (0.19--3.38) p = 0.764
  West            15.5 (0.73--329) p = 0.788                   5.56 (0.635--12.1) p = 0.121        **4.27 (1.20--15.1) p = 0.0246**

\*Values in parenthesis are 95% confidence intervals

^\#^Bolded data entries are significant at P \< 0.05.

Accuracy of outcome prediction
------------------------------

We then analyzed the accuracy of patient outcome prediction for each of the 2,411 gene sets. Initially, we tested five algorithms -- nearest centroid, diagonal linear discriminant analysis (DLDA), compound covariate predictor, one-nearest and three-nearest neighbor predictor \[[@B28]\] and found that in our datasets nearest centroid and DLDA methods performed better than the others (data not shown) with similar performance to each other. For convenience, we used the nearest centroid method in subsequent analysis. With six large datasets containing more than 100 samples, we estimated the prediction accuracy of each gene set by external validation. We measured prediction accuracy for each pair of 30 training-testing datasets and for a total of 30 predictions (Table [6](#T6){ref-type="table"}). The best gene set was the gene set 11823860_ST2, with prediction accuracy, sensitivity, and specificity of 67.55%, 70.56%, and 57.16%, respectively (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). The individual prediction accuracy with the 11823860_ST2 gene set was as high as 0.7464 when the training-testing pair was Pawitan-van de Vijver and as low as 0.54 74 when the training-testing pair was Wang-Bild (Table [6](#T6){ref-type="table"}). The individual prediction accuracy was not related to the differences in microarray platforms or patient characteristics (data not shown). We also analyzed the accuracy of patient outcome prediction with nine datasets with more than ten samples for each of the two groups. Again, the gene set 11823860_ST2 was the best with a prediction accuracy, sensitivity, and specificity of 0.6578, 0.6895, and 0.566, respectively (Additional data file [3](#S3){ref-type="supplementary-material"}, Supplementary Table 8).

###### 

Prediction accuracy of the 11823860_ST2 gene set in external validation

  training        testing         \*GTG   GTP    PTG   PTP   \*\*accuracy   sensitivity   specificity
  --------------- --------------- ------- ------ ----- ----- -------------- ------------- -------------
  Bild            Miller          128     49     17    19    0.6901         0.7232        0.5278
  Bild            Pawitan         89      41     7     15    0.6842         0.6846        0.6818
  Bild            Sotiriou_2      85      32     11    17    0.7034         0.7265        0.6071
  Bild            Van de Vijver   165     67     11    37    0.7214         0.7112        0.7708
  Bild            Wang            128     55     42    51    0.6486         0.6995        0.5484
  Miller          Bild            37      24     17    17    0.5684         0.6066        0.5
  Miller          Pawitan         84      46     6     16    0.6579         0.6462        0.7273
  Miller          Sotiriou_2      77      40     7     21    0.6759         0.6581        0.75
  Miller          Van de Vijver   165     67     11    37    0.7214         0.7112        0.7708
  Miller          Wang            125     58     42    51    0.6377         0.6831        0.5484
  Pawitan         Bild            43      18     19    15    0.6105         0.7049        0.4412
  Pawitan         Miller          133     44     19    17    0.7042         0.7514        0.4722
  Pawitan         Sotiriou_2      87      30     11    17    0.7172         0.7436        0.6071
  Pawitan         Van de Vijver   173     59     12    36    0.7464         0.7457        0.75
  Pawitan         Wang            135     48     51    42    0.6413         0.7377        0.4516
  Sotiriou_2      Bild            38      23     18    16    0.5684         0.623         0.4706
  Sotiriou_2      Miller          129     48     19    17    0.6854         0.7288        0.4722
  Sotiriou_2      Pawitan         86      44     10    12    0.6447         0.6615        0.5455
  Sotiriou_2      Van de Vijver   164     68     12    36    0.7143         0.7069        0.75
  Sotiriou_2      Wang            131     52     43    50    0.6558         0.7158        0.5376
  Van de Vijver   Bild            41      20     21    13    0.5684         0.6721        0.3824
  Van de Vijver   Miller          136     41     21    15    0.7089         0.7684        0.4167
  Van de Vijver   Pawitan         99      31     12    10    0.7171         0.7615        0.4545
  Van de Vijver   Sotiriou_2      88      29     15    13    0.6966         0.7521        0.4643
  Van de Vijver   Wang            141     42     54    39    0.6522         0.7705        0.4194
  Wang            Bild            34      27     16    18    0.5474         0.5574        0.5294
  Wang            Miller          123     54     14    22    0.6808         0.6949        0.6111
  Wang            Pawitan         81      49     6     16    0.6382         0.6231        0.7273
  Wang            Sotiriou_2      76      41     7     21    0.669          0.6496        0.75
  Wang            Van de Vijver   154     78     8     40    0.6929         0.6638        0.8333
                                                                                          
  Total                           3175    1325   559   746   0.6755         0.7056        0.5716

\*GTG -- Good prognosis group predicted as Good; GTP -- Good prognosis group predicted as Poor; PTG -- Poor prognosis group predicted as Good; PTP -- Poor prognosis group predicted as poor

\*\*accuracy = (GTG+PTP)/(GTG+GTP+PTG+PTP); sensitivity = GTG/(GTG+GTP); specificity = PTP/(PTG+PTP)

###### 

Top 20 gene sets with high prediction accuracy (analysis with six datasets)

  Gene set                                          category   GTG    GTP    PTG   PTP   accurary   sensitivity   specificity
  ------------------------------------------------- ---------- ------ ------ ----- ----- ---------- ------------- -------------
  11823860_ST2                                      br         3175   1325   559   746   0.6755     0.7056        0.5716
  transferase activity                              mf         3264   1236   658   647   0.6737     0.7253        0.4958
  ligase activity                                   mf         3204   1296   633   672   0.6677     0.712         0.5149
  11823860_ST3                                      br         3200   1300   632   673   0.6672     0.7111        0.5157
  transcription factor activity                     mf         3268   1232   701   604   0.667      0.7262        0.4628
  16141321_SDC2                                     br         3169   1331   607   698   0.6661     0.7042        0.5349
  oxidoreductase activity                           mf         3209   1291   648   657   0.666      0.7131        0.5034
  14737219_CSR                                      br         3165   1335   606   699   0.6656     0.7033        0.5356
  12917485_ST9                                      br         3162   1338   611   694   0.6643     0.7027        0.5318
  catalytic activity                                mf         3209   1291   661   644   0.6637     0.7131        0.4935
  RNA polymerase II transcription factor activity   mf         3235   1265   689   616   0.6634     0.7189        0.472
  transport                                         bp         3186   1314   645   660   0.6625     0.708         0.5057
  transcription                                     bp         3241   1259   701   604   0.6624     0.7202        0.4628
  transporter activity                              mf         3171   1329   631   674   0.6624     0.7047        0.5165
  14737219_USR                                      br         3094   1406   555   750   0.6622     0.6876        0.5747
  12917485_ST7                                      br         3140   1360   602   703   0.662      0.6978        0.5387
  ATP binding                                       mf         3185   1315   647   658   0.662      0.7078        0.5042
  kinase activity                                   mf         3205   1295   669   636   0.6617     0.7122        0.4874
  metabolism                                        bp         3199   1301   666   639   0.6612     0.7109        0.4897
  regulation of progression through cell cycle      bp         3108   1392   575   730   0.6612     0.6907        0.5594

\*category: br -- breast and other cancer gene set; mf -- molecular functions; bp -- biological processes

\*\*GTG -- Good prognosis group predicted as Good; GTP -- Good prognosis group predicted as Poor; PTG -- Poor prognosis group identified as Good; PTP -- Poor prognosis group identified as Poor

\^ accuracy = (GTG+ PTP)/(GTP+GTP+PTG+PTP); sensitivity = GTG/(GTG+GTP); specificity = PTP/(PTG+PTP)

Best gene sets for prediction accuracy differ from those for prognosis
----------------------------------------------------------------------

Comparison of the top 20 prognostic gene sets for breast cancer survival (Table [4](#T4){ref-type="table"}) with the top 20 gene sets with high prediction accuracy (Table [7](#T7){ref-type="table"}) showed only three common gene sets (11823860_ST2, 14737219_USR, and 14737219_CSR). Interestingly, the gene sets shown in Table [7](#T7){ref-type="table"} were, in general, from higher categories in the gene ontology hierarchy, including transferase activity (MF), transcription factor activity (MF), transport (BP), and transcription (BP). Because gene sets in higher categories have more genes than those in lower categories, we reasoned that there might be a significant difference in gene set size between the gene sets in Table [4](#T4){ref-type="table"} and Table [7](#T7){ref-type="table"}. Thus, we compared the distribution of gene set sizes between the top 20 prognostic gene sets for survival (designated as prognosis gene sets, Table [4](#T4){ref-type="table"}) and the top 20 gene sets with high prediction accuracy (designated as predictor gene sets, Table [7](#T7){ref-type="table"}) and found a significant difference in sizes between prognosis and predictor gene sets (Figure [2](#F2){ref-type="fig"}; P = 1.34 × 10^-5^by unpaired *t*-test). The sizes of the top 20 prognosis gene sets ranged from 6 to 530 with a mean of 155.5 and a median of 72.5, whereas the sizes of the top 20 predictor gene sets ranged from 125 to 1,817 with a mean of 674.15 and a median of 502.5 (Figure [2](#F2){ref-type="fig"}). The trend was repeatedly observed when we varied the number of top n prognosis and predictor gene sets (n = 10, 50, 100, 150, and 200) for comparison. The P-values by unpaired *t*-test to compare the difference in sizes between the two gene sets were 2.42 × 10^-3^(n = 10), 6.46 × 10^-8^(n = 50), 3.34 × 10^-7^(n = 100), 3.02 × 10^-8^(n = 150), and 4.55 × 10^-8^(n = 200), respectively

![**Comparison of gene set sizes between best prognostic gene sets (group 1) and best gene predictive sets (group 2).** The number of genes in top 20 gene sets for group discrimination (PROG) and top 20 gene sets for prediction accuracy (PRED) is box plotted. P-value was inferred from an unpaired *t*-test.](1471-2164-9-177-2){#F2}

Discussion
==========

We have shown that a gene sets approach is effective in identifying prognostic gene sets over multiple gene expression datasets. We identified 11823860_ST2 gene set as the best prognostic gene set for breast cancer patients.

Our gene sets approach is fundamentally different from previous methods in that our method doesn\'t try to build a single gene set from gene expression and clinical data as previous methods did \[[@B2],[@B3],[@B13]\]. Instead, our method begins from multiple gene sets and datasets and exhaustively searches for the best gene set among the given gene sets. As more gene sets and datasets accumulate, our method always finds out a better gene set than before. Another advantage of our gene sets approach is that it assists us to understand the underlying biology of the clinical outcome because many gene sets are prepared using biological knowledge such as pathways, gene ontology, and protein domains \[[@B12],[@B21],[@B22]\]. In the analysis of breast cancer datasets, cell cycle or proliferation gene sets were the best for prognosis of survival or recurrence as judged by the log-rank test (Table [4](#T4){ref-type="table"}). This result is in agreement with many previous studies showing that cell proliferation signatures are the best predictors of prognosis of breast cancer patients \[[@B1],[@B2],[@B12]-[@B16],[@B18],[@B24],[@B29],[@B30]\].

Because poor overlap among independently developed prognostic gene sets has raised concerns over this type of diagnostic tool \[[@B10],[@B11]\], we examined the degree of overlap among the top 20 prognostic gene sets identified in our study. Again, we found relatively poor overlap among them, thus confirming previous results (data not shown). However, poor overlap among gene sets may not be as serious a problem as previously thought if different gene sets represent similar biological pathways and are congruent on outcome prediction \[[@B30]-[@B32]\]. This point was recently emphasized by Fan et al. \[[@B26]\] who showed congruence among four different gene expression-based predictors for breast cancer.

Pepe et al. \[[@B33]\] emphasized that strong statistical associations between prognostic markers and clinical outcomes do not necessarily imply good discriminative power of the marker. Thus, instead of reporting odds ratios or hazards ratios, one should report an objective prediction accuracy to prove the usefulness of the marker as a diagnostic, prognostic, or screening tool \[[@B33]-[@B35]\]. As such, we calculated the prediction accuracy of each gene set using six datasets containing over 100 samples. We emphasize that we performed only external validation to avoid over-fitted estimation of prediction accuracy. While Michiels et al. \[[@B7]\] showed that five of the seven datasets they analyzed did not classify patients better than by chance, at least for breast cancer, all six datasets that we analyzed classified patients even though we only used external validation.

When we prepared 2,411 gene sets, we included 32 gene sets previously identified as prognostic in breast and other cancers to evaluate their performance in multiple gene expression datasets. Among the included gene sets are the 70-gene signature (12490681_70 in Table [3](#T3){ref-type="table"}) \[[@B1],[@B13]\], 76-gene signature (15721473_T3 in Table [3](#T3){ref-type="table"}) \[[@B2]\], 21-gene signature (15591335_F1 in Table [3](#T3){ref-type="table"}) \[[@B6]\], and wound healing signature (14737219_CSR in Table [3](#T3){ref-type="table"}) \[[@B3],[@B12]\] (Table [3](#T3){ref-type="table"}). Through various analyses, we identified the 11823860_ST2 gene set as the best prognostic gene set in breast cancer. The 11823860_ST gene set was the best in two and four-means clustering and also in outcome prediction (Table [4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}, Supplementary Table 2 in Additional data file [1](#S1){ref-type="supplementary-material"}, and Supplementary Table 8 in Additional data file [3](#S3){ref-type="supplementary-material"}). The 11823860_ST2 gene set was also ranked high in three, five, and six-means clustering (Supplementary Table 1, 3, and [4](#T4){ref-type="table"} in Additional data file [1](#S1){ref-type="supplementary-material"}). The 11823860_ST2 gene set was originally identified as 231 genes significantly associated with clinical outcomes of 78 node-negative, untreated, and young patients with an age at diagnosis less than 55 years in a supervised analysis \[[@B13]\]. But, in our analysis with 12 datasets, the 11823860_ST2 gene set was also prognostic in independent patients with diverse clinical characteristics (both node-negative and positive, both treated and untreated patients of all ages), which was previously confirmed \[[@B1],[@B18]\]. Also, the 11823860_ST2 gene set was prognostic in most datasets irrespective of the used microarray platforms.

In van\'t Veer et al. \[[@B13]\]\'s work, 11823860_ST2 gene set was reduced to the famous 70-gene signature by optimizing the number of genes for maximum accuracy in leave-one-out cross validation \[[@B13]\]. The 70-gene signature has been validated in subsequent works and now undergoes a large scale prospective clinical trial \[[@B1]\]. But, our results indicate that using 231 genes might be better than using the 70-gene signature. Then, why 11823860_ST2 gene set performed better than the 70-gene signature? One reason is because we included in our analysis 12 different datasets produced using diverse microarray platforms with different gene contents. In this situation, gene sets containing many genes are likely to perform better than gene sets with a small number of genes because a greater proportion of prognostic genes are consistently present across all platforms. Indeed, the 11823860_ST2 gene set contains many genes (for example, cyclin E2, MCM6, MMP9, MP1, RAB6B, PK429, ESM1, and FLT1), in addition to 70 genes, involved in processes such as cell cycle, invasion and metastasis, angiogenesis, and signal transduction, processes up-regulated in poor prognosis group \[[@B13]\]. The tendency of gene sets with high prediction accuracy (Table [7](#T7){ref-type="table"}) having more genes than prognostic gene sets identified by log-rank test (Table [4](#T4){ref-type="table"}) may be explained in the same way (Figure [2](#F2){ref-type="fig"}).

One concern in our strategy is that by taking a certain number of pre-defined gene sets, it may just happen that one gene set will turn out significant. However, because the two procedures we perform, log-rank test and the estimation of prediction accuracy, evaluate at individual gene-set level whether a gene set is prognostic or not, we suppose that our method can effectively handle false positive predictions. Thus, even if a gene set is identified as the best among pre-defined gene sets, the two procedures, log-rank test and prediction accuracy, will evaluate if the identified gene set is significant or not.

Many microarray-based molecular studies have been criticized as noisy discovery due to problems such as small sample size, inappropriate statistical analysis leading to over-fitting of data, lack of independent validation, or validation with too small set \[[@B9],[@B36],[@B37]\]. In this regard, our work sets a good example for microarray-based discovery of prognostic gene sets. We included more than 1,700 samples in the analysis and applied complete external validation to avoid data over-fitting. Thus, we believe that gene sets found in our analysis are truly prognostic in breast cancer and not just a noisy discovery. Finally, although we focused only on breast cancer datasets in this work, our gene sets approach is equally applicable to other types of cancer or to studies that develop molecular signatures for predicting drug sensitivity of each patient to cancer drugs. We expect that, like gene set enrichment analysis and similar tools that have become useful for gene expression data analysis \[[@B21],[@B22]\], a gene sets approach will be useful for developing prognostic signatures for outcome prediction \[[@B23]\].

Conclusion
==========

The gene sets approach is an effective tool for selecting a prognostic gene set as well as for understanding the underlying biology for different patients\' outcomes. By applying a bottom-up approach with many gene sets, we could identify the biological processes and pathways that are important for prognosis of breast cancer patients. The importance of cell proliferation signatures in breast cancer prognosis has been repeatedly discovered, but our approach reinforces these previous findings \[[@B1],[@B2],[@B13],[@B15],[@B16],[@B18],[@B24],[@B30],[@B38]\]. Additionally, our approach is applicable to other types of cancer in which prognostic gene sets are less developed than breast cancer.

Methods
=======

Datasets
--------

We downloaded breast cancer gene expression datasets with clinical information from the gene expression omnibus \[[@B39]\], Stanford microarray database \[[@B40]\], or author\'s individual web pages \[[@B1],[@B2],[@B15]-[@B20],[@B26],[@B27],[@B38],[@B41]\]. See Table [1](#T1){ref-type="table"} for a complete list of datasets and their sources. We analyzed 12 datasets comprising 1,756 tissue samples.

Gene sets
---------

We prepared gene sets from diverse sources including gene ontology (GO) terms \[[@B42]\], GenMAPP \[[@B43]\] and KEGG pathways \[[@B44]\], and InterPro protein domain information \[[@B45]\] using the Affymetrix annotation file (2006 November version) downloaded from the Affymetrix web site (Table [2](#T2){ref-type="table"})\[[@B46]\]. We limited the gene set size between five and two thousands. We also included 32 well-known prognostic gene sets for breast and other cancers (Table [3](#T3){ref-type="table"}). For those 32 gene sets, we created a nomenclature for each gene set by combining the PubMed id of the reference and the source of the gene set in the reference. For example, 11823860_ST2 represents a gene set from the Supplementary Table [2](#T2){ref-type="table"} from van\'t Veer et al. \[[@B13]\] with a PubMed id of 118323860. The number of gene sets in each category is shown in Table [2](#T2){ref-type="table"}.

Preprocessing of microarray data
--------------------------------

The datasets that we analyzed included both single-channel Affymetrix and dual-channel cDNA microarray platforms. We used a gene symbol as a common identifier to map probe IDs across different platforms. When we mapped a gene set between two arrays, we used only genes common to both arrays. To analyze Affymetrix datasets, we consistently used expression values computed by MAS5 algorithms to ensure similar processing, normalized each sample by a global mean method to a target density of 1,000, floored low expression values to 100, log-transformed each value by base two, merged replicate probes for the same gene by an average value, and finally mean-centered each gene within a dataset \[[@B47]\]. To analyze cDNA datasets, we initially filtered out missing values when the percentage of missing values was greater than 30%, imputed missing values by the k-nearest neighbor method, merged replicate probes by an average value, and finally mean-centered each gene. We used the GEPAS web service \[[@B48]\] to filter and impute missing values \[[@B49]\].

Statistical analysis
--------------------

For each dataset and gene set, we applied k-means clustering with k = 2, 3, 4, 5, and 6 to divide each sample into two, three, four, five, or six groups based on the gene expression pattern of the gene set and applied the log-rank test to infer the statistical significance of differences in survival between the groups. We used a Kaplan-Meier plot to show the differences in survival. We applied the nearest-centroid prediction rule, one of the simplest class prediction methods, to estimate the accuracy of prediction for each patient\'s outcome \[[@B7]\]. To briefly describe, the nearest-centroid prediction rule first calculates a centroid for each group. The centroid is the average gene expression for each gene in each group. Then, with a new sample, the method calculates two distances between the gene expression value of the new sample and each of the two centroids and assigns the new sample to the group with the smaller distance. For each gene set, we defined two average profiles (good and poor) as vectors of the average expression values of genes in a gene set in patients with good and poor prognoses. Good prognosis patients were defined as relapse-free or overall survival over five years, whereas poor prognosis patients were deceased within five years. We classified each patient in the validation set according to the Euclidean distance between the gene expression of the patient and the two average profiles. We performed external validation using six large datasets containing more than 100 samples. For external validation, we calculated two average (good and poor) profiles using only samples in one dataset and predicted patient outcomes in the other five datasets and performed external validation for all training-testing pairs of six datasets (30 pairs). We used R language \[[@B50]\] for statistical analysis and python programming language \[[@B51]\] for data processing.
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**Additional data file 2**contains tables (5--7) showing adjusted hazard ratios of the gene set 11823860_ST2 for available clinical parameters in Sotiriou_2, van de Vijver, and Sorlie_1 datasets, respectively.
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**Additional data file 3**is a Supplementary table (8) showing top 20 gene sets with high prediction accuracy in independent validation using nine datasets.
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